The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities - GBI Research Reports

The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities

The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities - GBI Research Reports
The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities
Published Mar 25, 2010
145 pages — Published Mar 25, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

SummaryGBI Research has released its research - 'The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities'. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global marketsScopeThe scope of this report includes:- Annualized market data for the blood disorders market from 2001 to 2009, forecast forward to 2016 - Analysis of the leading therapeutic segments including anemia, thrombosis, hemophilia, neutropenia and thrombocytopenia - Analysis of the blood disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan - Market characterization of the blood disorders market including market size, annual cost of therapy, sales volume and treatment usage patterns - Key drivers and barriers that have a significant impact on the market - Coverage of pipeline molecules in various phases of drug development - Competitive benchmarking of leading companies. The key companies studied in this report are Amgen, Inc., Sanofi-Aventis, Bristol-Myers Squibb, Centocor Ortho Biotech Inc., and Baxter. - Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global blood disorders marketReasons to buyThe report will enhance your decision making capability. It will allow you to - Align product portfolio to the markets with high growth potential - Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth - Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety - Develop key strategic initiatives by understanding key focus areas of leading companies - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

  
Source:
Document ID
GBIHC028MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents38
1.1 List of Tables62
1.2 List of Figures83
Global Blood Disorders Market: Introduction112
2.1 GBI Research Report Guidance121
3 Global Blood Disorders Market: Market Overview1314
3.1 Introduction131
3.2 Revenue Forecasts for the Global Blood Disorders Market141
3.2.1 Sales Value141
3.2.2 Sales Volume151
Annual Cost of Therapy161
3.2.4 Treatment Usage Patterns172
3.2.4.1 Diseased Population191
3.2.4.2 Treatment Seeking Population191
3.2.4.3 Diagnosed Population201
3.2.4.4 Prescription Population211
Generics Share in the Global Blood Disorders Market222
3.3 Blood Disorders Market Drivers241
3.3.1 Steady Increase in the Prevalence Population, Particularly in Anemia, in the Top Five Countries in Europe 241
3.3.2 Rapid Uptake of Biologics Products due to Better Efficacy and Safety in Diseases Such as Anemia, Hemophilia and Neutropenia241
3.3.3 Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable 241
3.3.4 Increase in Conditions Such as Cancer and Cardiovascular Events will Increase the Prevalence of Blood Disorders251
3.4 Blood Disorders Market Restraints251
3.4.1 Low Diagnosis Rate as the Contemporary Diagnostic Tools are Unable to Diagnose the Severe Forms of Blood Disorders251
3.4.2 Patent Expiries of Major Blockbusters Including Plavix, Lovenox, Aranesp, Neulasta, Procrit and Others Pose a Threat to Leading Players in the Market251
3.4.3 The Clearance of the Regulatory Pathway in the US Will Open up the World s Largest Pharmaceutical Market to Biosimilar Players261
3.4.4 Sluggish Growth in the Annual Cost of Therapy for Blood Disorders is Expected To Drive Down the Growth Rate261
4 Global Blood Disorders Market: Therapeutic Landscape2761
4.1 Anemia Market271
4.1.1 Introduction271
4.1.2 Sales Value271
4.1.3 Sales Volume282
4.1.4 Annual Cost of Therapy301
4.1.5 Treatment Usage Patterns311
4.1.5.1 Diseased Population322
4.1.5.2 Treatment Seeking Population341
4.1.5.3 Diagnosed Population351
4.1.5.4 Prescription Population 361
4.1.6 Geographical Segmentation364
4.1.7 Generics Share of the Global Anemia Market402
4.2 Thrombosis Market421
4.2.1 Introduction421
4.2.2 Sales Value422
4.2.3 Sales Volume441
Annual Cost of Therapy452
4.2.5 Treatment Usage Patterns471
4.2.5.1 Diseased Population481
4.2.5.2 Treatment Seeking Population491
4.2.5.3 Diagnosed Population501
4.2.5.4 Prescription Population511
4.2.6 Geographical Segmentation523
4.2.7 Generics Share of the Global Thrombosis Market551
4.3 Hemophilia Market561
4.3.1 Introduction562
4.3.2 Sales Value581
4.3.3 Sales Volume591
4.3.4 Annual Cost of Therapy602
4.3.5 Treatment Usage Patterns621
4.3.5.1 Diseased Population631
4.3.5.2 Treatment Seeking Population632
4.3.5.3 Diagnosed Population651
4.3.5.4 Prescription Population 661
4.3.6 Geographical Segmentation673
4.3.7 Generics Share in the Global Hemophilia Market702
4.4 Neutropenia Market721
4.4.1 Introduction721
4.4.2 Sales Value731
4.4.3 Sales Volume741
Annual Cost of Therapy752
4.4.5 Treatment Usage Patterns771
4.4.5.1 Diseased Population781
4.4.5.2 Treatment Seeking Population791
4.4.5.3 Diagnosed Population801
4.4.5.4 Prescription Population 811
4.4.6 Geographical Segmentation823
4.4.7 Generics Share in the Global Neutropenia Market853
5 Global Blood Disorders Market: Geographical Landscape8827
5.1 Geographical Break-up883
5.2 The US911
5.2.1 Sales Value911
5.2.2 Sales Volume921
5.2.3 Annual Cost of Therapy931
5.2.4 Treatment Usage Patterns941
5.2.4.1 Diseased Population951
5.2.4.2 Treatment Seeking Population961
5.2.4.3 Diagnosed Population971
5.2.4.4 Prescription Population 971
5.3 Top Five Countries in Europe981
5.3.1 Sales Value982
5.3.2 Sales Volume1001
5.3.3 Annual Cost of Therapy1012
5.3.4 Treatment Usage Patterns1031
5.3.4.1 Diseased Population1041
5.3.4.2 Treatment Seeking Population1051
5.3.4.3 Diagnosed Population1061
5.3.4.4 Prescription Population 1071
5.4 Japan1071
5.4.1 Sales Value1071
5.4.2 Sales Volume1082
5.4.3 Annual Cost of Therapy1101
5.4.4 Treatment Usage Patterns1111
5.4.4.1 Diseased Population1121
5.4.4.2 Treatment Seeking Population1131
5.4.4.3 Diagnosed Population1131
5.4.4.4 Prescription Population 1141
6 Global Blood Disorders Market: Pipeline Analysis1158
6.1 Introduction1151
6.1.1 Research and Development Pipeline Anemia1161
6.1.2 Research and Development Pipeline Thrombosis1171
6.1.3 Research and Development Pipeline Hemophilia1171
6.1.4 Research and Development Pipeline Neutropenia1181
Profiles of Key Late-Stage Drugs in the Blood Disorders Market1191
6.2.1 Xarelto 1191
6.2.1.1 Introduction1191
6.2.1.2 Mechanism of Action1191
6.2.1.3 Clinical Trial Management1191
6.2.2 AVE-50261201
6.2.2.1 Introduction1201
6.2.2.2 Mechanism of Action1201
6.2.2.3 Clinical Trial Management1201
6.2.3 Apixaban1211
6.2.3.1 Introduction1211
6.2.3.2 Mechanism of Action1211
6.2.3.3 Clinical Trial Management1211
6.2.4 Hematide1211
6.2.4.1 Introduction1211
6.2.4.2 Mechanism of Action1211
6.2.4.3 Clinical Trial Management1211
6.2.5 MAXY G341221
6.2.5.1 Introduction1221
6.2.5.2 Mechanism of Action1221
6.2.5.3 Clinical Trial Management1221
7 Global Blood Disorders Market: Competitive Landscape1236
7.1 Market Share Analysis: Blood Disorders1231
7.2 Competitive Profiling1241
7.2.1 Amgen1241
7.2.1.1 Product Portfolio1251
7.2.2 Sanofi-Aventis1261
7.2.2.1 Product Portfolio1261
7.2.3 Bristol-Myers Squibb1261
7.2.3.1 Product Portfolio1271
7.2.4 Centocor Ortho Biotech Inc.1271
7.2.4.1 Product Portfolio1271
7.2.5 Baxter1281
7.2.5.1 Product Portfolio1281
8 Global Blood Disorders Market: Strategic Consolidations12911
8.1 Overview1291
8.1.1 GlaxoSmithKline Acquired JCR Pharmaceuticals Co Ltd. in December 20091301
8.1.2 Biovitrum AB Acquired Swedish Orphan International AB in November 20091311
8.1.3 LFB Biotechnologies Acquired GTC Biotherapeutics Inc in November 20091311
8.1.4 Watson Pharmaceuticals Acquired Arrow Group in June 20091311
8.1.5 Sanofi-Aventis SA Acquired Medley Pharmaceuticals in April 20091311
8.1.6 Merck &Co. Acquired Insmed Corporation in February 20091321
8.1.7 Pfizer Acquired Wyeth in January 20091321
8.2 R&D Licensing Agreements 1321
8.2.1 Deals by Indication1321
8.2.2 Deals by Phase1331
8.2.3 Deals by Geography1331
8.2.4 Deals by Licensing Type1341
8.2.5 Deals by Value ($)1351
8.2.6 Preclinical1351
8.2.6.1 Evotec/Vifor Anemia Program1351
8.2.6.2 Intravenous Recombinant Factor IX1361
8.2.6.3 CB8131361
8.2.6.4 rhFVIIa Program1361
8.2.7 Phase II1361
8.2.7.1 Fostamatinib Disodium1371
8.2.7.2 Intravenous Recombinant Factor IX1371
8.2.7.3 Recombinant Porcine Factor VIII, B-domain Deleted1371
8.2.7.4 FX061381
8.2.7.5 Betrixaban 1381
8.2.8 Phase III1381
8.2.8.1 MAXY-G34 1381
8.2.9 Filed/Approved1391
8.2.9.1 Sodium Ferric Gluconate Complex In Sucrose Injection1391
8.2.9.2 Theragran-H1391
8.2.9.3 KINLYTIC1391
9 Global Blood Disorders Market: Appendix1406
9.1 Market Definitions1401
9.2 Abbreviations1401
9.3 Research Methodology1414
9.3.1 Coverage 1411
9.3.2 Secondary Research1421
9.3.3 Primary Research1421
9.3.4 Forecasts1421
9.3.4.1 Epidemiology-based Forecasting1422
9.3.5 Expert Panel Validation1441
9.4 Contact Us1451
9.5 Disclaimer1451
9.6 Sources1451

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities" Mar 25, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Blood-Disorders-Therapeutics-Analysis-and-Market-Forecasts-to-2016-Better-and-More-Cost-Effective-Treatment-Options-Create-Opportunities-2115-38>
  
APA:
GBI Research Reports. (2010). The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities Mar 25, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Blood-Disorders-Therapeutics-Analysis-and-Market-Forecasts-to-2016-Better-and-More-Cost-Effective-Treatment-Options-Create-Opportunities-2115-38>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.